Regenerative Biologics

Regenerative Biologics, Inc. (RBI) is a biotechnology company specializing in the development and commercialization of human cell and tissue-based products (HCT/Ps) derived from placental tissues. The company's portfolio includes amniotic membrane, amniotic fluid, and umbilical cord-derived products designed to promote healing in wound care, orthopedics, and ophthalmology. RBI utilizes proprietary processing techniques to preserve the natural biological properties of the tissue, including essential growth factors and extracellular matrix components. Their products, such as Amnio-Max and Amnio-Fluid, are used by clinicians to treat chronic wounds, sports injuries, and degenerative conditions. The company is headquartered in St. Louis, Missouri, and operates within the regulatory framework for Section 361 HCT/Ps.